RFK Jr. Initiates Sweeping HHS Restructuring, Thousands of Jobs Cut
Table of Contents
April 2, 2025
Health and Human Services Secretary Robert F. Kennedy Jr. has begun a massive overhaul of the agency, resulting in the layoff of thousands of employees and sparking concerns about the future of public health initiatives in the United States.
Topline
Health and Human Services Secretary Robert F. Kennedy Jr. initiated a significant restructuring of the agency on Tuesday, April 1, 2025, resulting in the layoff of thousands of workers. Thes cuts include leaders of divisions responsible for critical functions such as regulating food and drugs, studying chronic diseases and environmental disaster risks, and targeting H.I.V. prevention. This sweeping reorganization comes as Kennedy has long expressed skepticism about widely accepted public health research and recommendations, raising concerns among experts and the public alike.
Health and Human Services Secretary Robert F. Kennedy Jr.arriving at the official residence of the … More
PA Images via Getty Images
Key Facts
Kennedy began issuing “reduction in force” notices to employees late Monday and early Tuesday, according to multiple reports. These cuts are impacting senior leaders and entire departments, signaling a profound shift in the agency’s structure and priorities.
Kennedy announced last thursday a plan to eliminate 10,000 jobs at HHS. This includes significant reductions at key agencies: 18% of employees at the centers for Disease Control and Prevention (CDC), 15% of employees at the Food and Drug administration (FDA), 6% of workers at the National Institutes of Health (NIH), and 4% of employees at the Centers for Medicare and Medicaid Services (CMS).
Several top officials at the National Institutes of Health (NIH) have been asked to relocate to remote locations or placed on administrative leave. Jeanne Marrazzo, who succeeded Anthony Fauci as director of the National Institute of Allergy and Infectious Diseases, along wiht other senior leaders, were reportedly offered reassignments to locations such as Alaska, Montana, and Oklahoma, with a tight deadline to respond.
Jonathan Mermin, Director of the CDC’s Center for H.I.V. and sexually transmitted diseases, has been placed on administrative leave. Furthermore, research teams focused on preventing H.I.V. transmission between mother and child have been entirely eliminated.
Key positions at the FDA have also been affected. Peter Stein, director of the FDA Office of New Drugs, and the division’s policy office have been cut. Brian King, Director of the FDA Center for Tobacco Products, has been placed on administrative leave. The FDA’s Office of Strategic Programs, including its director, Sridhar Mantha, has been entirely eliminated.
Multiple other CDC divisions have been impacted by the layoffs.These include the National Center for Chronic Disease Prevention and Health Promotion; the National Center for Injury Prevention and Control; the National Center for H.I.V., Viral Hepatitis, STD and TB Prevention; the National Center for Environmental health; the Global Health Center; and the National Center on Birth Defects and Developmental Disabilities.
Impact on Public Health Initiatives
The sweeping layoffs at the HHS raise serious concerns about the future of public health initiatives in the U.S. The CDC, for example, plays a crucial role in monitoring and preventing disease outbreaks, and significant staff reductions could hamper its ability to respond effectively to future health crises. Similarly, cuts at the FDA could slow down the approval process for new drugs and medical devices, possibly delaying access to life-saving treatments for Americans.
The elimination of research teams focused on preventing H.I.V. transmission between mother and child is notably alarming. These programs have been instrumental in reducing the rate of perinatal H.I.V. transmission in the U.S.,and their elimination could lead to a resurgence of this preventable condition.
These changes could have a disproportionate impact on vulnerable populations,including low-income communities and people of color,who frequently enough rely on government-funded health programs for their care.
Chief Critic
Robert califf,former FDA commissioner under Presidents Joe Biden and Barack Obama,expressed strong concerns about the restructuring. “The FDA as we’ve known it is finished, with most of the leaders with institutional knowlege and a deep understanding of product advancement and safety no longer employed,” Califf wrote on linkedin on Tuesday morning.
The FDA as we’ve known it is finished, with most of the leaders with institutional knowledge and a deep understanding of product development and safety no longer employed.
Robert Califf, former FDA Commissioner
What To Watch for
Approximately 873 employees at the national Institute of Occupational Safety and Health (NIOSH), representing two-thirds of its staff, are expected to be laid off by June 30, according to a letter to union officials reported by CBS News on Tuesday. The agency’s National Personal Protective Technology Laboratory, which is responsible for vetting personal protective medical equipment like N95 masks, is among the divisions facing complete staff cuts. NIOSH, currently part of the CDC, will be integrated into a new Administration for a Healthy America, along with other divisions, including the Substance Abuse and Mental Health Services Administration, as part of Kennedy’s broader restructuring plan.
Tangent
Dr. Peter marks,the FDA’s top vaccine official,was reportedly pushed out of the agency last week. In his resignation letter, Marks cited “misinformation and lies” spread by Kennedy about vaccines as a contributing factor. Marks stated he would resign as the agency’s director of the center for Biologics Evaluation and Research effective April 5.Marks joined the FDA in 2012 and played a significant role in expediting the distribution of the COVID-19 vaccine during the first Trump administration.
Key Background
Kennedy announced the 10,000 job cuts last week, adding to the 10,000 employees who had already accepted a layoff package. His goal is to reduce the agency’s size from 82,000 to 62,000 employees, aligning with the Elon Musk-led Department of Government efficiency’s initiative to substantially reduce the federal workforce.The agency will close five of its ten regional offices and reduce the number of divisions from 28 to 15,aiming to “streamline the functions of the department” and eliminate “many redundant units.” Two divisions—NIOSH and the Agency for toxic substances and Disease Registry—currently under the CDC, will be transferred to the new Administration for a Healthy America. Services for older adults and people with disabilities, currently managed by the Administration for Community Living, will be divided among three separate divisions. The agency estimates these cuts will save approximately $1.8 billion. While Kennedy attributes the restructuring to reducing “bureaucratic sprawl,” he has consistently expressed a desire to re-evaluate long-accepted medical practices,research,and regulations,even after his appointment as HHS secretary.
Potential Counterarguments and Rebuttals
While Secretary Kennedy argues that these cuts are necessary to streamline the HHS and eliminate redundancies, critics contend that they will weaken the agency’s ability to protect public health.Some may argue that a smaller government is a more efficient government, but the potential consequences of these cuts on critical public health programs cannot be ignored.
Moreover, Kennedy’s skepticism towards established medical practices raises concerns that these cuts are driven by ideological motives rather than sound fiscal policy. It is indeed crucial to ensure that any restructuring of the HHS is based on evidence-based decision-making and prioritizes the health and well-being of all Americans.
Expert Analysis and Implications
The implications of these changes extend beyond the immediate job losses. The restructuring could lead to a decline in morale among remaining employees, making it more difficult to attract and retain top talent at the HHS. This, in turn, could further weaken the agency’s ability to fulfill its mission.
Moreover, the cuts could create opportunities for special interest groups to influence public health policy. With fewer government employees overseeing the industry, pharmaceutical companies and other powerful lobbies may have greater sway over regulations and guidelines.
It is indeed essential for Congress and the public to closely monitor the impact of these changes and hold Secretary Kennedy accountable for ensuring that the HHS continues to effectively protect the health of all Americans.
Further Reading
- RFK Jr.’s 10,000 Health Job Cuts: CDC, FDA, Medicare And Medicaid Services Reportedly Affected (Forbes)
- Who Is Dr. peter Marks? FDA’s Top Vaccine Official Quits, Citing RFK Jr.’s ‘Misinformation And Lies.’ (Forbes)
- Here’s What An RFK Jr. Health Role In A Trump Administration Could Look Like: Vaccine Skepticism, Fluoride Ban (Forbes)
RFK Jr.’s HHS Overhaul: Experts Weigh In on the sweeping Public Health Reforms and Job Cuts
World Today News: Dr. Anya sharma, thank you for joining us today. Wiht Health and Human Services Secretary Robert F. Kennedy Jr.’s extensive restructuring of the HHS, including significant layoffs, we’re seeing a major shift in the agency’s direction. How concerning are these changes for the future of public health in the United States?
Dr. Anya Sharma: It’s a critical moment. The scale of this restructuring,especially the planned reduction of 20,000 employees,is unprecedented in recent history. These changes introduce significant uncertainty. The implications for public health initiatives are multifaceted and deeply concerning.
Understanding the Impact of HHS Restructuring
World Today News: Can you elaborate on specific areas where these changes might have the most significant impact?
Dr. Anya Sharma: The changes are poised to have both direct and indirect impacts on health and wellbeing.
Disease Prevention and Control: The CDC is responsible for monitoring and responding to disease outbreaks.With an 18% reduction in staff [[3]] this could compromise its capacity to respond to public health emergencies like pandemics, and outbreaks of infectious diseases.
Drug and Medical Device approval: The FDA’s approval processes are essential for American citizens to access safe and effective medical treatments. The loss of experienced staff could slow down these vital procedures, which will delay access to life-saving treatments [[3]].
Research and Advancement: reduced staffing in the NIH may limit the ability to conduct critical research on chronic diseases, environmental hazards, and other public health concerns. This will hinder our ability to advance medical knowledge and improve treatment options for those who need them.
Impact on Vulnerable Populations: Many government-funded health programs, like Medicare and Medicaid, will be affected by these cuts. this will disproportionately affect low-income communities,the elderly,and people of color [[3]].
World Today News: The article mentions concerns about the FDA and the departure of key officials. Can you discuss how these leadership changes at the FDA could affect the agency’s functions?
Dr. Anya Sharma: The FDA’s mission is to ensure the safety and effectiveness of drugs, biologics, and medical devices. The removal of senior leaders, along with the restructuring of essential divisions, presents cause for alarm. The loss of directors of key offices like the Office of new Drugs and the Center for Tobacco Products can slow down approvals for new lifesaving medications and devices [[1]]. The FDA’s ability to effectively regulate the health product industry could diminished, which could ultimately compromise public health.The FDA’s
